Solventum Corporation $SOLV Shares Sold by Blair William & Co. IL

Blair William & Co. IL lessened its holdings in Solventum Corporation (NYSE:SOLV) by 8.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,053 shares of the company’s stock after selling 957 shares during the quarter. Blair William & Co. IL’s holdings in Solventum were worth $762,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. KLP Kapitalforvaltning AS increased its holdings in Solventum by 20.2% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 61,965 shares of the company’s stock worth $4,699,000 after buying an additional 10,400 shares during the period. Barrett & Company Inc. increased its holdings in Solventum by 206.2% in the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock worth $30,000 after buying an additional 268 shares during the period. Ameritas Advisory Services LLC acquired a new position in Solventum in the 2nd quarter worth approximately $60,000. HighMark Wealth Management LLC increased its holdings in Solventum by 8.7% in the 2nd quarter. HighMark Wealth Management LLC now owns 2,349 shares of the company’s stock worth $178,000 after buying an additional 188 shares during the period. Finally, SOA Wealth Advisors LLC. increased its holdings in Solventum by 1,397.3% in the 2nd quarter. SOA Wealth Advisors LLC. now owns 554 shares of the company’s stock worth $42,000 after buying an additional 517 shares during the period.

Solventum Trading Down 0.2%

Shares of NYSE:SOLV opened at $71.41 on Friday. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $85.92. The firm has a market capitalization of $12.38 billion, a price-to-earnings ratio of 33.06, a price-to-earnings-growth ratio of 2.91 and a beta of 0.50. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. The business’s 50 day moving average price is $72.65 and its 200-day moving average price is $72.01.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.24. The company had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities research analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SOLV. Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Solventum in a research report on Wednesday, October 8th. Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a research report on Tuesday, July 1st. Morgan Stanley upgraded Solventum from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, UBS Group started coverage on Solventum in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $84.89.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.